Joseph Stringer
Stock Analyst at Needham
(3.62)
# 796
Out of 4,876 analysts
323
Total ratings
43.06%
Success rate
7.71%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Joseph Stringer
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ALNY Alnylam Pharmaceuticals | Maintains: Buy | $320 → $377 | $318.25 | +18.46% | 22 | Jun 26, 2025 | |
| CDTX Cidara Therapeutics | Maintains: Buy | $36 → $54 | $48.03 | +12.43% | 13 | Jun 23, 2025 | |
| PHAT Phathom Pharmaceuticals | Maintains: Buy | $28 | $9.55 | +193.19% | 52 | Jun 6, 2025 | |
| VIR Vir Biotechnology | Reiterates: Buy | $14 | $5.31 | +163.65% | 18 | May 22, 2025 | |
| GILD Gilead Sciences | Reiterates: Hold | n/a | $107.62 | - | 6 | May 21, 2025 | |
| INZY Inozyme Pharma | Downgrades: Hold | $12 | $4.00 | +200.00% | 20 | May 16, 2025 | |
| ANNX Annexon | Maintains: Buy | $16 → $11 | $2.45 | +348.98% | 19 | May 13, 2025 | |
| APLS Apellis Pharmaceuticals | Maintains: Buy | $40 → $29 | $18.40 | +57.61% | 20 | May 7, 2025 | |
| RYTM Rhythm Pharmaceuticals | Maintains: Buy | $66 → $72 | $61.45 | +17.18% | 24 | May 7, 2025 | |
| VRTX Vertex Pharmaceuticals | Reiterates: Hold | n/a | $443.40 | - | 6 | May 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $60 → $55 | $39.78 | +38.26% | 21 | Apr 30, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $60 | $29.83 | +101.14% | 17 | Apr 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $22 | $11.84 | +85.81% | 22 | Apr 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $90 | $32.88 | +173.72% | 17 | Apr 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Hold | n/a | $0.93 | - | 13 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $10 | $1.30 | +669.23% | 17 | Mar 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Hold | n/a | $27.54 | - | 8 | Nov 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $37 | $22.21 | +66.59% | 6 | Jan 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $32 → $18 | $10.73 | +67.75% | 2 | Aug 24, 2021 |
Alnylam Pharmaceuticals
Jun 26, 2025
Maintains: Buy
Price Target: $320 → $377
Current: $318.25
Upside: +18.46%
Cidara Therapeutics
Jun 23, 2025
Maintains: Buy
Price Target: $36 → $54
Current: $48.03
Upside: +12.43%
Phathom Pharmaceuticals
Jun 6, 2025
Maintains: Buy
Price Target: $28
Current: $9.55
Upside: +193.19%
Vir Biotechnology
May 22, 2025
Reiterates: Buy
Price Target: $14
Current: $5.31
Upside: +163.65%
Gilead Sciences
May 21, 2025
Reiterates: Hold
Price Target: n/a
Current: $107.62
Upside: -
Inozyme Pharma
May 16, 2025
Downgrades: Hold
Price Target: $12
Current: $4.00
Upside: +200.00%
Annexon
May 13, 2025
Maintains: Buy
Price Target: $16 → $11
Current: $2.45
Upside: +348.98%
Apellis Pharmaceuticals
May 7, 2025
Maintains: Buy
Price Target: $40 → $29
Current: $18.40
Upside: +57.61%
Rhythm Pharmaceuticals
May 7, 2025
Maintains: Buy
Price Target: $66 → $72
Current: $61.45
Upside: +17.18%
Vertex Pharmaceuticals
May 6, 2025
Reiterates: Hold
Price Target: n/a
Current: $443.40
Upside: -
Apr 30, 2025
Maintains: Buy
Price Target: $60 → $55
Current: $39.78
Upside: +38.26%
Apr 9, 2025
Reiterates: Buy
Price Target: $60
Current: $29.83
Upside: +101.14%
Apr 9, 2025
Reiterates: Buy
Price Target: $22
Current: $11.84
Upside: +85.81%
Apr 8, 2025
Reiterates: Buy
Price Target: $90
Current: $32.88
Upside: +173.72%
Mar 7, 2025
Reiterates: Hold
Price Target: n/a
Current: $0.93
Upside: -
Mar 4, 2025
Downgrades: Hold
Price Target: $10
Current: $1.30
Upside: +669.23%
Nov 8, 2024
Reiterates: Hold
Price Target: n/a
Current: $27.54
Upside: -
Jan 24, 2024
Upgrades: Buy
Price Target: $37
Current: $22.21
Upside: +66.59%
Aug 24, 2021
Maintains: Buy
Price Target: $32 → $18
Current: $10.73
Upside: +67.75%